December 23, 2009 - CIRC Trial Continues as Planned


A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


DSMB Completes its First Review

December 23, 2009CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.

Data from the international trial that is testing the effectiveness of the FDA-cleared AutoPulse® Non-invasive Cardiac Support Pump, in comparison to manual chest compressions alone, was fully reviewed by the Data Safety Monitoring Board.  The Board, which consists of several physicians and a statistician, is responsible for ensuring the trial is proceeding safely and in accordance with protocols, and has the authority to halt the trial.  If the Data Safety Monitoring Board were to have any concerns about the safety of the trial, the Board would be required to take action to insure patient safety and/or protocol adherence.   More than 700 cases from the two arms of the trial were reviewed.

The principal investigator for the trial is Lars Wik, M.D., Ulleval University, Oslo, Norway.  Dr. Wik and colleagues from Houston, Texas; Fox Valley Region, Wisconsin; Hillsborough County, Florida; Vienna, Austria; and Nijmegen, The Netherlands, are conducting the research into whether the AutoPulse-integrated chest compressions are superior or equivalent to manual compressions alone for patients suffering cardiac arrests tied to heart conditions.  Each site has gone through extensive training around very strict protocols established for the trial, including proper use of the AutoPulse.

“We are pleased with the significant progress the CIRC Trial is making. We note that an earlier trial of the AutoPulse, ‘ASPIRE’, was halted prematurely after its first review due to futility and concerns about safety, and if similar issues had been identified with CIRC, the DSMB would have halted enrollment,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “Instead, we got a clean check-up and are continuing ahead in this important effort.”

“While some clinicians are waiting for the results of this trial to validate the contribution mechanical CPR can make to improving outcomes from sudden cardiac death, recent reports presented at the American Heart Association Resuscitation Science Symposium add to the continuing science supporting the AutoPulse.  A presentation from St. Charles County, Missouri showed a marked likelihood of return of spontaneous circulation in cardiac arrest patients treated with AutoPulse, and data from a Statewide California Registry showed the risk of adverse events associated with the AutoPulse to be no greater than with manual CPR while improving return of spontaneous circulation by forty-five percent,”  Mr. Packer added. “As the economy improves we look for the growth of the AutoPulse to accelerate.”

The AutoPulse has been commercially available for over four years and is in use worldwide. It is manufactured by ZOLL Medical Corporation, which is the CIRC trial's sponsor.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual  Report on Form 10-K filed with the SEC on December 10, 2009. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL and AutoPulse are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.